AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|
19.6 C
New York
Friday, July 24, 2026

Tag: bacterial infections

newssourceFORcompanyinformationcontent1releasesmarket

EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

Fedora Pharmaceuticals Expands Scientific Advisory Board with Appointment of Drs. Michael Dudley, Keith Micetich, and Jürgen Bulitta

Drs. Michael N. Dudley, Keith A. Micetich, and Jürgen B. Bulitta join advisory board of renowned infectious disease leaders at Fedora Pharmaceuticals.

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Ad hoc announcement pursuant to Art. 53 LR

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections

Allschwil, Switzerland, July 29, 2025

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

RESEARCH SHOWS EARLY CANCER CELLS CAN BE RAPIDLY DETECTED THROUGH ELECTRONIC SEMICONDUCTORS

CLEVELAND, July 15, 2025 /PRNewswire/ -- IdentifySensors Biologics, a leader in digital diagnostic technologies, has demonstrated that its electronic biosensors used to detect pathogens...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBacterial infections

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers